2. 筋萎縮性側索硬化症 [臨床試験数:508,薬物数:530(DrugBank:146),標的遺伝子数:170,標的パスウェイ数:221

Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-002228-28-IT
(EUCTR)
01/09/201412/06/2014STEMALS-IIA double blind, placebo controlled, parallel groups, multicenter study on filgrastim in amyotrophic lateral sclerosis - STEMALS-II Amyotrophic lateral sclerosis (ALS) is a severe progressive neurological disorder characterized by a selective degeneration of spinal, bulbar, and cortical motor neurons.;Therapeutic area: Not possible to specifyTrade Name: TEVAGRASTIM
Product Name: filgrastim
Trade Name: MANNITOLO 18% LDB
Product Name: MANNITOLO 18%
Trade Name: PERFALGAN
Product Name: PARACETAMOLO
Università degli Studi di Torino e Azienda Ospedaliera Città della Salute e della Scienza di TorinoNULLNot RecruitingFemale: yes
Male: yes
90Phase 2Italy
2NCT02236065
(ClinicalTrials.gov)
August 20148/9/2014Combination Therapy of Cord Blood and G-CSF for Patients With Brain Injury or Neurodegenerative DisordersA Pilot Study of Combination Therapy of Allogeneic Umbilical Cord Blood and Granulocyte-colony Stimulating Factor for Patients With Brain Injury or Neurodegenerative DisordersBrain Injury;Cerebral Palsy;Amyotrophic Lateral Sclerosis;Parkinson's DiseaseProcedure: Umbilical cord blood therapy;Biological: FilgrastimMinYoung Kim, M.D.NULLCompleted19 Years75 YearsAll10N/AKorea, Republic of
3NCT01825551
(ClinicalTrials.gov)
November 201213/3/2013The Effect of GCSF in the Treatment of ALS PatientsThe Effect of Granulocyte Colony Stimulating Factor (GCSF) in the Treatment of Amyotrophic Lateral Sclerosis (ALS) Patients Referred to Tehran Imam Khomeini and Shariati Hospital Centers in 2013Amyotrophic Lateral SclerosisDrug: Granulocyte Colony Stimulating Factor;Drug: PlaceboTehran University of Medical SciencesNULLCompleted18 Years85 YearsBoth40Phase 2/Phase 3Iran, Islamic Republic of
4NCT00397423
(ClinicalTrials.gov)
December 20068/11/2006G-CSF Treatment for Amyotrophic Lateral Sclerosis: A RCT Study Assessing Clinical ResponseGranulocyte-Colony Stimulating Factor Treatment for Amyotrophic Lateral Sclerosis: A Randomized Control Trial Study Assessing Clinical ResponseAmyotrophic Lateral SclerosisDrug: Granulocyte Colony Stimulating Factor;Drug: NSPeking UniversityNULLCompleted18 Years65 YearsBoth40Phase 2China
5NCT00298597
(ClinicalTrials.gov)
March 20061/3/2006Influence of G-CSF and EPO on Associative Learning and Motor SkillsInfluence of G-CSF and EPO on Associative Learning and Motor SkillsChronic Stroke;Amyotrophic Lateral SclerosisDrug: granulocyte - colony stimulating factor (G-CSF);Drug: erythropoetin (EPO)University Hospital MuensterNULLCompleted18 YearsN/ABoth180Phase 2Germany